London, UK – Ipsos Healthcare, the global healthcare division of Ipsos, has added the Stroke Prevention in Atrial Fibrillation (SPAF) Monitor to its syndicated Cardiovascular Therapy Monitor Portfolio.

The SPAF Monitor, which arrives at a critical juncture in this therapy area, allows clients to understand and track SPAF treatment across the EU5, US, South Korea, Japan and Brazil. Q1 2013 data is now available and reveals current drug shares, doctors’ current and future prescribing intentions, and the attributes driving their decision-making. Ipsos Healthcare’s Cardiovascular Therapy Monitor Portfolio also covers Venous Thromboembolism (VTE), Pulmonary Arterial Hypertension (PAH) and Hypertension.

Dr Sabina Heinz, Head of Ipsos Healthcare’s Cardiovascular Therapy Monitor Portfolio, commented:

“For decades, Stroke Prevention in Atrial Fibrillation has been treated with Warfarin – which puts a considerable burden on the patient – or simply, with aspirin. Now, the SPAF treatment landscape has been transformed by the introduction of Novel Oral Anticoagulants (NOACs). Against this backdrop, our SPAF monitor will answer critical questions such as, ‘What split of drugs are doctors giving to their patients right now?’, and, more importantly, ‘What do they expect to be doing in 12 months’ time’?”